46.86
前日終値:
$46.84
開ける:
$46.92
24時間の取引高:
47.28M
Relative Volume:
3.34
時価総額:
$101.69B
収益:
$47.64B
当期純損益:
$5.42B
株価収益率:
17.55
EPS:
2.67
ネットキャッシュフロー:
$13.09B
1週間 パフォーマンス:
-5.81%
1か月 パフォーマンス:
-2.11%
6か月 パフォーマンス:
-18.26%
1年 パフォーマンス:
+14.18%
Bristol Myers Squibb Co Stock (BMY) Company Profile
名前
Bristol Myers Squibb Co
セクター
電話
(609) 252-4621
住所
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
BMY
Bristol Myers Squibb Co
|
46.86 | 101.69B | 47.64B | 5.42B | 13.09B | 2.67 |
![]()
LLY
Lilly Eli Co
|
762.73 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
149.79 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
NVO
Novo Nordisk Adr
|
73.77 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
![]()
ABBV
Abbvie Inc
|
185.30 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
115.77 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
2025-04-22 | 開始されました | Piper Sandler | Overweight |
2024-12-16 | アップグレード | Jefferies | Hold → Buy |
2024-12-10 | 再開されました | BofA Securities | Neutral |
2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
2024-11-13 | アップグレード | Daiwa Securities | Neutral → Outperform |
2024-11-12 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-10-25 | ダウングレード | Citigroup | Buy → Neutral |
2024-10-17 | 開始されました | Bernstein | Mkt Perform |
2024-07-29 | ダウングレード | Barclays | Overweight → Equal Weight |
2024-03-11 | ダウングレード | Societe Generale | Buy → Hold |
2024-02-06 | ダウングレード | Redburn Atlantic | Buy → Neutral |
2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
2023-11-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2023-11-09 | 開始されました | Deutsche Bank | Hold |
2023-11-02 | ダウングレード | Daiwa Securities | Outperform → Neutral |
2023-10-27 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2023-10-27 | アップグレード | HSBC Securities | Reduce → Hold |
2023-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
2023-10-20 | 再開されました | UBS | Neutral |
2023-07-14 | 開始されました | HSBC Securities | Reduce |
2023-07-10 | 開始されました | SVB Securities | Market Perform |
2023-06-28 | 開始されました | Daiwa Securities | Outperform |
2023-03-06 | 開始されました | Jefferies | Hold |
2023-01-17 | 開始されました | Cantor Fitzgerald | Overweight |
2022-11-18 | 開始されました | Credit Suisse | Neutral |
2022-10-10 | ダウングレード | Guggenheim | Buy → Neutral |
2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
2022-06-03 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2022-04-06 | 再開されました | Morgan Stanley | Underweight |
2021-12-17 | 開始されました | Goldman | Buy |
2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
2021-11-01 | ダウングレード | Argus | Buy → Hold |
2021-07-27 | 再開されました | Truist | Buy |
2021-04-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2021-04-13 | アップグレード | Truist | Hold → Buy |
2020-11-16 | アップグレード | Societe Generale | Hold → Buy |
2020-11-10 | 再開されました | Bernstein | Mkt Perform |
2020-11-06 | ダウングレード | Gabelli & Co | Buy → Hold |
2020-10-19 | アップグレード | Guggenheim | Neutral → Buy |
2020-09-29 | 開始されました | Berenberg | Buy |
2020-07-28 | 開始されました | Raymond James | Outperform |
2020-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
2020-02-27 | 開始されました | Barclays | Equal Weight |
2020-01-06 | 再開されました | Citigroup | Buy |
2019-12-13 | アップグレード | Argus | Hold → Buy |
2019-11-22 | 再開されました | Morgan Stanley | Equal-Weight |
2019-10-17 | 再開されました | BofA/Merrill | Buy |
2019-08-14 | アップグレード | Atlantic Equities | Neutral → Overweight |
2019-05-28 | 開始されました | Goldman | Buy |
2019-05-20 | ダウングレード | Argus | Buy → Hold |
2019-05-03 | アップグレード | Barclays | Equal Weight → Overweight |
2019-05-03 | 再開されました | JP Morgan | Overweight |
2019-01-15 | アップグレード | Societe Generale | Sell → Buy |
2018-10-22 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Bristol Myers Squibb Co (BMY) 最新ニュース
Bristol Myers Squibb (BMY) Collaborates on Alzheimer's Drug Deve - GuruFocus
Bristol-Myers (NYSE:BMY) Squibb Dividend Update Reflects Steady Healthcare NYSE Composite - Kalkine Media
Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends - Yahoo
BioNTech and Bristol Myers Squibb Collaborate on BNT327, a PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com
Bristol Myers Squibb to present positive new data on lymphoma treatment - Pharmafile
Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BM - GuruFocus
Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BMY Stock News - GuruFocus
Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies - Caixin Global
Bristol Myers Squibb declares quarterly dividend of $0.62 per share By Investing.com - Investing.com Nigeria
Bristol Myers Squibb Announces Dividend - marketscreener.com
Bristol-Myers Expands in Cancer Care With $1.35B OncoACP3 Deal - Insider Monkey
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Therapy - geneonline.com
Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress - MSN
Bristol Myers Squibb (BMY) Shares Cross 5% Yield Mark - Nasdaq
Myocardial Infarction Market Is Booming So Rapidly 2025-2032 - openPR.com
Vanguard Health Care Fund's Strategic Moves: A Closer Look at Bristol-Myers Squibb Co - Yahoo Finance
Bristol-Myers Squibb (BMY) Announces Positive Data From the Pivotal Phase 3 POETYK PsA-1 Trial - MSN
Bristol Myers Squibb (BMY) Achieves Strong Results with Breyanzi in Lymphoma Study - GuruFocus
Bristol Myers: positive phase 2 data in lymphoma - MarketScreener
Bristol Myers (BMY) Reports Promising Results from Lymphoma Stud - GuruFocus
Schizophrenia Drugs Market Size, Share & Forecast 2025 | Major - openPR.com
Bristol-Myers Squibb (BMY) Stock Analysis: Healthcare Giant with a 14.77% Potential Upside - DirectorsTalk Interviews
Business development leadership team - Bristol Myers Squibb
BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Treatment - geneonline.com
Rockland Trust Co. Sells 20,035 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Jim Cramer on Bristol Myers: “We Need to See That Stock Back Up at $60” - Insider Monkey
BioNTech and Bristol Myers Squibb Partner to Develop Bispecific Antibody Targeting PD-L1 and VEGF-A for Tumor Treatment - geneonline.com
Bristol-Myers Squibb’s SWOT analysis: stock outlook amid Cobenfy growth and pipeline potential - Investing.com
Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button' - Endpoints News
Bristol Myers (BMY) Showcases Promising New Data on Targeted Pro - GuruFocus
Bristol-Myers Promotes Attorney To Lead Corporate Affairs - Law360
BioNTech and Bristol Myers Squibb Partner to Develop BNT327 Antibody Targeting PD-L1 and VEGF-A Pathways in Tumors - geneonline.com
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu Compared with Placebo in Adults with Psoriatic Arthritis - marketscreener.com
Bristol-Myers stock holds steady as Cantor maintains neutral rating By Investing.com - Investing.com South Africa
BMY Reports Positive Data on Sotyktu From Arthritis Study - TradingView
Bristol Myers Squibb promotes Wendy Bartie to lead corporate affairs - PR Week UK
Bristol Myers: new data to be presented in hematology - marketscreener.com
Bristol-Myers stock holds steady as Cantor maintains neutral rating - Investing.com
Bristol Myers Squibb presents protein degradation data at EHA By Investing.com - Investing.com India
Bristol Myers Squibb presents protein degradation data at EHA - Investing.com
Bristol Myers Squibb Sets Q2 2025 Earnings Date: Key Financial Results Coming July 31 - Stock Titan
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025 - The Joplin Globe
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider - MSN
Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu - Yahoo Finance
Bristol Myers at Goldman Sachs Conference: Strategic Insights on Growth - Investing.com Australia
Bristol Myers bolsters radiopharma portfolio with PhiloChem deal - BioPharma Dive
Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Bristol Myers (BMY) Sees Promising Results for Sotyktu in Phase 3 Trial - GuruFocus
BioNTech and Bristol Myers Squibb Collaborate on PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com
Bristol-Myers Squibb To Present At Goldman Sachs Global Conference; Webcast At 10:00 AM ET - Nasdaq
Bristol Myers Squibb Co (BMY) 財務データ
収益
当期純利益
現金流量
EPS
Bristol Myers Squibb Co (BMY) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Hickey Benjamin | President, RayzeBio Org. |
May 09 '25 |
Sale |
38.01 |
97 |
3,702 |
0 |
Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. |
Apr 25 '25 |
Buy |
47.58 |
4,250 |
202,215 |
83,513 |
Shanahan Karin | EVP, Glob. Prod. Dev. & Supply |
Apr 01 '25 |
Option Exercise |
0.00 |
3,306 |
0 |
15,489 |
Plenge Robert M | EVP, Chief Research Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
11,255 |
0 |
20,148 |
Meyers Gregory Scott | EVP, Chief Digital & Tech Off. |
Mar 10 '25 |
Option Exercise |
0.00 |
23,150 |
0 |
26,937 |
Shanahan Karin | EVP, Glob. Prod. Dev. & Supply |
Mar 10 '25 |
Option Exercise |
0.00 |
20,423 |
0 |
22,339 |
Lenkowsky Adam | EVP, Chief Commercial Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
16,684 |
0 |
20,017 |
Poole Ahn Amanda | EVP, Chief People Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
7,164 |
0 |
8,546 |
LEUNG SANDRA | EVP, General Counsel |
Mar 10 '25 |
Option Exercise |
0.00 |
48,718 |
0 |
386,496 |
Hoch Lynelle | President, Cell Therapy Org. |
Mar 10 '25 |
Option Exercise |
0.00 |
7,446 |
0 |
7,920 |
大文字化:
|
ボリューム (24 時間):